Adam Sperling, MD, PhD, discusses future research directions with idecabtagene vicleucel for the treatment of patients with multiple myeloma.

Adam Sperling, MD, PhD,a physician at theDana-Farber Cancer Institute,andaninstructor in medicine at Harvard Medical School,discussesfutureresearch directionswithidecabtagene vicleucel(ide-cel; Abecma)for the treatment of patients with multiple myeloma.

Ongoing studies are examining the use ofide-cel, as well as otherCAR T-cell therapies like ciltacabtagene autoleucel,in early lines of therapy, according to Sperling.These studies are being done inpatients whohaverelapsedquickly after their first-line therapy, Sperling notes. These patients are high risk,and are often primaryrefractoryto their first line oftherapy orhaverelapsed within6months to1 year of undergoing autologousstem celltransplantation, Sperling explains.Currently, notenough data exist todeterminewhetherthe durability of response will be better if this modality isutilizedin earlier lines,but more information is anticipated, Sperling says.

Additionally,patients whohave beentreated withide-celdidnotreceive any other therapy,which differs from howpatientswithmultiple myeloma aregenerallytreated, Sperlingadds; they did not receive continuous treatment or maintenance therapy. However, ongoing trials are examining whether the durability of responses achieved with this approach can be improvedif other therapiesare given after CAR T-celltherapy, or incombination with this modality, Sperlingconcludes.

See more here:

Dr. Sperling on Future Research Directions With Ide-Cel in Multiple Myeloma - OncLive

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *